DE60306503D1 - Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion - Google Patents

Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Info

Publication number
DE60306503D1
DE60306503D1 DE60306503T DE60306503T DE60306503D1 DE 60306503 D1 DE60306503 D1 DE 60306503D1 DE 60306503 T DE60306503 T DE 60306503T DE 60306503 T DE60306503 T DE 60306503T DE 60306503 D1 DE60306503 D1 DE 60306503D1
Authority
DE
Germany
Prior art keywords
maintenance
improving
cognitive function
statin
statin therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60306503T
Other languages
English (en)
Other versions
DE60306503T2 (de
Inventor
Sean Lilienfeld
M Gutterman
John Glasspool
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60306503D1 publication Critical patent/DE60306503D1/de
Application granted granted Critical
Publication of DE60306503T2 publication Critical patent/DE60306503T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
DE60306503T 2002-04-02 2003-03-28 Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion Expired - Lifetime DE60306503T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
US369285P 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (2)

Publication Number Publication Date
DE60306503D1 true DE60306503D1 (de) 2006-08-10
DE60306503T2 DE60306503T2 (de) 2007-06-21

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60306503T Expired - Lifetime DE60306503T2 (de) 2002-04-02 2003-03-28 Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Country Status (22)

Country Link
EP (1) EP1492539B1 (de)
JP (1) JP2005525391A (de)
KR (1) KR100986194B1 (de)
CN (1) CN100528164C (de)
AT (1) ATE331523T1 (de)
AU (1) AU2003226753B2 (de)
BR (1) BR0308293A (de)
CA (1) CA2480275C (de)
CY (1) CY1105545T1 (de)
DE (1) DE60306503T2 (de)
DK (1) DK1492539T3 (de)
EA (1) EA013069B1 (de)
ES (1) ES2268393T3 (de)
HK (1) HK1079688A1 (de)
IL (2) IL164317A0 (de)
MX (1) MXPA04009535A (de)
NO (1) NO20044698L (de)
NZ (1) NZ536111A (de)
PL (1) PL211160B1 (de)
PT (1) PT1492539E (de)
UA (1) UA79605C2 (de)
WO (1) WO2003082298A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2005232447A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of Alzheimers disease
EP1604686A1 (de) * 2004-06-08 2005-12-14 Axonyx, Inc. Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Also Published As

Publication number Publication date
ATE331523T1 (de) 2006-07-15
KR100986194B1 (ko) 2010-10-07
CN100528164C (zh) 2009-08-19
CA2480275A1 (en) 2003-10-09
PL371551A1 (en) 2005-06-27
IL164317A0 (en) 2005-12-18
AU2003226753A1 (en) 2003-10-13
IL164317A (en) 2010-04-29
AU2003226753B2 (en) 2007-06-28
BR0308293A (pt) 2004-12-28
JP2005525391A (ja) 2005-08-25
PL211160B1 (pl) 2012-04-30
WO2003082298A1 (en) 2003-10-09
EA200401295A1 (ru) 2005-02-24
ES2268393T3 (es) 2007-03-16
CY1105545T1 (el) 2010-07-28
CN1642555A (zh) 2005-07-20
EP1492539A1 (de) 2005-01-05
NZ536111A (en) 2006-03-31
MXPA04009535A (es) 2005-01-25
KR20040096608A (ko) 2004-11-16
DK1492539T3 (da) 2006-10-30
HK1079688A1 (en) 2006-04-13
PT1492539E (pt) 2006-11-30
EP1492539B1 (de) 2006-06-28
EA013069B1 (ru) 2010-02-26
DE60306503T2 (de) 2007-06-21
NO20044698L (no) 2004-10-29
CA2480275C (en) 2011-08-16
UA79605C2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
TW200633694A (en) Composition and method for treating asthma
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
HUP0300043A2 (en) Method and composition for the treatment of pain
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
WO2003066806A3 (en) Therapeutic use of aziridino compounds
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition